# OnCo record nuvation-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/nuvation-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "nuvation-bio" ;
  schema:name "Nuvation Bio"@en ;
  schema:alternateName "Nuvation Bio Inc."@en ;
  schema:description "Nuvation Bio is a United States-based biotechnology company running 6 late-stage cancer trials of Taletrectinib, AB-106 and NUV-1511 in non-small-cell lung cancer, HR-positive / HER2-negative breast cancer and prostate cancer."@en ;
  schema:url <https://onco.cc/companies/nuvation-bio/>, <https://www.nuvationbio.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.nuvationbio.com>, <https://clinicaltrials.gov/search?lead=Nuvation%20Bio%20Inc.>, <https://www.nuvationbio.com/pipeline> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:drugs <https://onco.cc/drugs/safusidenib/>, <https://onco.cc/drugs/nuv-1511/>, <https://onco.cc/drugs/taletrectinib/> ;
  onco:trials <https://onco.cc/trials/nct07154706/>, <https://onco.cc/trials/nct06564324/>, <https://onco.cc/trials/nct04919811/>, <https://onco.cc/trials/nct04395677/> .